These recommendations were based on the ability to prevent mother-to-child transmission of HIV. The ACTG 076 trial demonstrated a twothirds reduction of mother-to-child transmission of the human immunodeficiency virus (HIV) can be achieved by initiating AZT therapy prior to the 34th week of pregnancy, by giving this drug intravenously during labor, and by giving the child AZT following delivery. 4 Another study has demonstrated that administration of zidovudine to the mother alone in the last few weeks of pregnancy can reduce the rate of transmission by approximately 50%. s It also has been shown that giving a single dose of nevirapine to women at the onset of labor and to their infants shortly after birth will reduce the rate of vertical HIV transmission. 6 Obstetrical interventions also may reduce transmission. A meta-analysis showed that the rate of transmission can be reduced further by cesarean section. 7 It also has been shown that having an extended period of time between the performance of amniotomy and delivery increases the risk of maternal-fetal transmission of HIV. 8 An argument can be made for a second screening for HIV infection at delivery because there is a 14% risk of transmission by breastfeeding. 9 Therefore, knowing that a woman has seroconverted during the prenatal care period would allow her physician to recommend against breastfeeding. In addition, if a woman who tested negative during the prenatal period were found to be positive at delivery, she would have been recently infected. 
